{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:59:29Z","timestamp":1789365569429,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,30]],"date-time":"2014-11-30T00:00:00Z","timestamp":1417305600000},"content-version":"vor","delay-in-days":3926,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1111\/j.1198-743x.2004.00751.x","type":"journal-article","created":{"date-parts":[[2004,3,3]],"date-time":"2004-03-03T06:40:40Z","timestamp":1078296040000},"page":"242-246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Activity of linezolid against Gram-positive cocci isolated in French hospitals as determined by three in-vitro susceptibility testing methods"],"prefix":"10.1016","volume":"10","author":[{"given":"C.","family":"Muller-Serieys","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.B.","family":"Drugeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lascols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J.","family":"Soussy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1198-743X.2004.00751.x_bib1","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/AAC.42.12.3251","article-title":"The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria","volume":"42","author":"Swaney","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1198-743X.2004.00751.x_bib2","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1517\/13543784.8.8.1195","article-title":"Mechanism of action of oxazolidinone antibacterial agents","volume":"8","author":"Shinabarger","year":"1999","journal-title":"Expert Opin Invesigt Drugs"},{"key":"10.1111\/j.1198-743X.2004.00751.x_bib3","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jac\/45.6.797","article-title":"Activity of linezolid against Gram\u2010positive cocci possessing genes conferring resistance to protein synthesis inhibitors","volume":"45","author":"Fines","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1198-743X.2004.00751.x_bib4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0966-842X(97)01032-9","article-title":"Oxazolidinones: new antibacterial agents","volume":"5","author":"Ford","year":"1997","journal-title":"Trends Microbiol"},{"key":"10.1111\/j.1198-743X.2004.00751.x_bib5","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1128\/AAC.42.10.2752","article-title":"In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci","volume":"42","author":"Struwig","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1198-743X.2004.00751.x_bib6","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1086\/313597","article-title":"Use of linezolid, an oxazolidinone, in the treatment of multidrug\u2010resistant gram\u2010positive bacterial infections","volume":"30","author":"Chien","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1198-743X.2004.00751.x_bib7","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2165\/00003495-200059040-00007","article-title":"Linezolid","volume":"59","author":"Clemett","year":"2000","journal-title":"Drugs"},{"key":"10.1111\/j.1198-743X.2004.00751.x_bib8","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1128\/AAC.40.4.839","article-title":"In vitro activities of U\u2010100592 and U\u2010100766, novel oxazolidinone antibacterial agents","volume":"40","author":"Zurenko","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1198-743X.2004.00751.x_bib9","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1128\/AAC.43.6.1469","article-title":"Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans","volume":"43","author":"Goldstein","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1198-743X.2004.00751.x_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1469-0691.1999.tb00099.x","article-title":"In vitro activity of linezolid and eperezolid against anaerobic bacteria","volume":"5","author":"Edlund","year":"1999","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1198-743X.2004.00751.x_bib11","series-title":"Communiqu\u00e9 2002","author":"Comit\u00e9 de l'antibiogramme","year":"2002"},{"key":"10.1111\/j.1198-743X.2004.00751.x_bib12","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/jac\/43.4.569","article-title":"Comparative in\u2010vitro activities of moxifloxacin, trovafloxacin, quinupristin\/dalfopristin and linezolid against staphylococci","volume":"43","author":"Von Eiff","year":"1999","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 1","key":"10.1111\/j.1198-743X.2004.00751.x_bib13","first-page":"268","article-title":"Multicentre evaluation of linezolid antimicrobial activity in Europe","volume":"7","author":"Ballow","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1198-743X.2004.00751.x_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1469-0691.2000.006006331.x","article-title":"In vitro activity of linezolid against staphylococci","volume":"6","author":"Cuny","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1198-743X.2004.00751.x_bib15","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/AAC.44.4.1062-1066.2000","article-title":"In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin\u2010dalfopristin against staphylococci and enterococci, including vancomycin\u2010intermediate and \u2013 resistant strains","volume":"44","author":"Rybak","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1198-743X.2004.00751.x_bib16","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/jac\/46.6.931","article-title":"Susceptibility of gram\u2010positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group","volume":"46","author":"Henwood","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1198-743X.2004.00751.x_bib17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jac\/47.1.77","article-title":"In vitro activity of linezolid against multiply resistant Gram\u2010positive clinical isolates","volume":"47","author":"Cercenado","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1198-743X.2004.00751.x_bib18","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/jac\/42.6.721","article-title":"The in\u2010vitro activity of linezolid (U\u2010100766) and tentative breakpoints","volume":"42","author":"Wise","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1198-743X.2004.00751.x_bib19","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1128\/AAC.44.7.1838-1841.2000","article-title":"Comparative in vitro activities of linezolid, quinupristin\u2013dalfopristin, moxifloxacin, and trovafloxacin against erythromycin\u2010susceptible and \u2010resistant streptococci","volume":"44","author":"Betriu","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1198-743X.2004.00751.x_bib20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/jac\/45.2.225","article-title":"Activity of linezolid against multi\u2010resistant gram\u2010positive bacteria from diverse hospitals in the United Kingdom","volume":"45","author":"Johnson","year":"2000","journal-title":"J Antimicrob Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14631062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14631062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:17:08Z","timestamp":1761117428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14631062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S1198743X14631062"],"URL":"https:\/\/doi.org\/10.1111\/j.1198-743x.2004.00751.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2004,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of linezolid against Gram-positive cocci isolated in French hospitals as determined by three in-vitro susceptibility testing methods","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1198-743X.2004.00751.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 European Society of Clinical Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}